Rising zoonotic diseases are driving growth in infectious disease diagnostics market
The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
How Does The Market Size Of The Emerging Infectious Disease Diagnostics Market Compare Between 2026 And 2030?
The emerging infectious disease diagnostics market size has demonstrated substantial growth in recent years. It is projected to expand from $24.34 billion in 2025 to $26.75 billion in 2026, achieving a compound annual growth rate (CAGR) of 9.9%. Historically, this growth can be attributed to an increasing frequency of infectious disease outbreaks, the expansion of public health surveillance programs, rising investments in laboratory infrastructure, a growing demand for rapid diagnostic solutions, and advancements in molecular testing technologies.
The emerging infectious disease diagnostics market size is expected to experience significant expansion over the next few years. It is projected to reach $38.54 billion by 2030, driven by a compound annual growth rate (CAGR) of 9.6%. This growth during the forecast period is attributed to an increased focus on pandemic preparedness, the rising adoption of next-generation sequencing diagnostics, the expansion of decentralized testing models, the growing integration of AI-driven diagnostic analytics, and increased government funding for disease monitoring. Major trends anticipated in this period include the increasing deployment of rapid molecular diagnostic platforms, the rising use of point-of-care testing solutions, the growing integration of genomic surveillance tools, the expansion of multiplex diagnostic assays, and an enhanced focus on early outbreak detection.
Access Your Free Sample Report For In-Depth Market Analysis:
What Key Factors Are Affecting The Emerging Infectious Disease Diagnostics Market Demand?
An increase in zoonotic disease occurrences is anticipated to drive the future expansion of the emerging infectious disease diagnostics market. Zoonotic illnesses are defined as infections transferable from animals to humans, stemming from bacteria, viruses, parasites, or fungi. This rise in zoonotic disease cases is mainly attributed to heightened human-wildlife contact, habitat loss, and worldwide travel, all of which aid the spread of pathogens between different species. Emerging infectious disease diagnostics play a crucial role in managing zoonotic conditions through early detection and precise identification of pathogens. This facilitates rapid intervention, successful treatment, and improved control of outbreaks, consequently limiting animal-to-human transmission. A relevant example from June 2025, cited by the Centers for Disease Control and Prevention, a US government public-health agency, indicated that 48 states and the District of Columbia documented 2,770 human arboviral disease cases in 2023, representing an increase from 1,247 cases in 2022. These figures included 2,022 hospitalizations (73%) and 208 deaths (8%), with West Nile virus identified as the predominant domestic arboviral disease reported in 2023, making up 2,628 cases (95%). Consequently, the increasing occurrence of zoonotic diseases is a key factor propelling the emerging infectious disease diagnostics market.
How Is The Emerging Infectious Disease Diagnostics Market Organized By Segment Classification?
The emerging infectious disease diagnostics market covered in this report is segmented –
1) By Infection Type: Viral, Bacterial, Fungal, Other Infections
2) By Disease Type: Respiratory Infections, Gastrointestinal Infections, Sexually Transmitted Infections (STIs), Other Disease Types
3) By Technology: Polymerase Chain Reaction (PCR), Isothermal Nucleic Acid Amplification Technology (INAAT), Next-Generation Sequencing (NGS), Immunodiagnostics, Other Technologies
4) By Application: Laboratory Testing, Point-of-Care Testing
5) By End-User: Hospitals And Clinics, Diagnostics Laboratories, Other End-Users
Subsegments:
1) By Viral: Respiratory Viruses, Hepatitis Viruses, HIV and Retroviruses, Arboviruses, Herpesviruses, Gastrointestinal Viruses, Emerging Viral Infections
2) By Bacterial: Tuberculosis (TB), Methicillin-Resistant Staphylococcus Aureus (MRSA), Escherichia Coli (E. coli) Infections, Streptococcus and Pneumococcus Infections, Clostridium Infections, Neisseria, Emerging Drug-Resistant Bacteria
3) By Fungal: Candidiasis, Aspergillosis, Cryptococcosis, Histoplasmosis, Coccidioidomycosis, Pneumocystis Pneumonia (PCP), Emerging Fungal Infections
4) By Other Infections: Parasitic Infections, Protozoan Infections, Prion Diseases, Helminthic Infections, Non-Pathogenic or Environmental Infections
What Trends Are Influencing Changes In The Emerging Infectious Disease Diagnostics Market?
Leading firms within the emerging infectious disease diagnostics market are prioritizing the creation of novel solutions, including temperature-activated generation of signal (TAGS) technology, to bolster rapid detection, efficient high-throughput screening, and enhanced outbreak response mechanisms. This TAGS technology represents a sophisticated multiplex PCR approach, leveraging controlled temperature activation to produce optical signals. This allows for the concurrent identification of numerous pathogens from one sample, facilitating extensive syndromic testing, quicker result delivery, and streamlined laboratory operations. Illustratively, in September 2024, F. Hoffmann-La Roche AG, a diagnostics and biotechnology company based in Switzerland, introduced the cobas Respiratory flex test. This TAGS-powered molecular diagnostic is engineered to identify as many as 12 common respiratory viruses from a single patient sample, offering automated high-throughput analysis, customizable pathogen panel setup, and seamless integration with cobas 5800, 6800, and 8800 systems. The cobas Respiratory flex contributes to more prompt detection of infectious agents, reinforces clinical decision-making, and aids in improved readiness for new disease challenges.
Who Are The Industry Participants Involved In The Emerging Infectious Disease Diagnostics Market?
Major companies operating in the emerging infectious disease diagnostics market are Roche Diagnostics, Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Siemens Healthineers, Becton Dickinson and Company, Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Agilent Technologies Inc., Hologic Inc., Illumina Inc., bioMérieux SA, QuidelOrtho Corporation, Bio-Rad Laboratories, Inc., Qiagen N.V., DiaSorin S.p.A., Randox Laboratories Ltd., Meridian Bioscience Inc., Sekisui Diagnostics LLC, Copan Diagnostics, Co-Diagnostics Inc., T2 Biosystems Inc.
Get The Full Emerging Infectious Disease Diagnostics Market Report:
Which Region Accounts For The Largest Portion Of The Emerging Infectious Disease Diagnostics Market?
North America was the largest region in the emerging infectious disease diagnostics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the emerging infectious disease diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Emerging Infectious Disease Diagnostics Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Emerging Infectious Disease Diagnostics Market 2026, By The Business Research Company
Cancer Diagnostics Market Report 2026
https://www.thebusinessresearchcompany.com/report/cancer-diagnostics-global-market-report
Transplant Diagnostics Market Report 2026
https://www.thebusinessresearchcompany.com/report/transplant-diagnostics-global-market-report
Blood Transfusion Diagnostics Market Report 2026
https://www.thebusinessresearchcompany.com/report/blood-transfusion-diagnostics-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
